Author

Paul Graham Wyatt

University of DundeeORCID 0000-0002-0397-245XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Organism:bacteria (other)· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Laura A. T. CleghorniD· 4 shared Simon Richard GreeniD· 4 shared Clifton E. BarryiD· 3 shared Kevin D. ReadiD· 3 shared Laura Guijarro-López· 3 shared Peter C. RayiD· 3 shared Dirk SchnappingeriD· 2 shared Helena I. BoshoffiD· 2 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

Laura A. T. CleghornORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Thienothiazolocarboxamides: rapidly cidal agents causing catastrophic thiol collapse in Mycobacterium tuberculosis.

Sangmi Oh, Gareth Prosser, Helena I.M. Boshoff, Simon Richard Green, Neha Quadir, Jose Santinni O. Roma, Ashish Kumar, Nilesh Mukundan, Sarah Hanson, Jansy Passiflora Sarathy, Kirsteen I Buchanan, Peter C. Ray, Paul G. Wyatt, Thomas R. Ioerger, Adrian L. Schwan, , Clifton E. Barry

This paper identifies thienothiazolocarboxamides as rapidly cidal antituberculosis agents that cause thiol collapse in Mycobacterium tuberculosis through EthA-mediated activation.

bioRxiv · Nov 9, 2026 · PreprintMicrobiology

DDU384: A new preclinical candidate for the treatment of Tuberculosis

Simon R. Green, Kirsteen I. Buchanan, Helena I. Boshoff, Paul J. Koovits, Dinakaran Murugesan, Cristina De Cozar-Gallardo, Ana Yepes, Eik Hoffmann, Lisa M. Massoudi, Paul J. Converse, Oliver D. Komm, Laura Guijarro-López, Patricia Casado, Paul Scullion, Adolfo García-Pérez, , Laura A. T. Cleghorn

This paper identifies DDU384, a new compound with potent in vivo efficacy against tuberculosis in murine models, showing potential to improve current treatment options.

bioRxiv · Oct 27, 2026 · PreprintMicrobiology

Identification and Evaluation of dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis

Claire Naylor, Gareth A. Prosser, Tracy Bayliss, Lila Berle, Joshua B. Wallach, Heather Kim, Rodrigo Aguilera Olvera, Stephen Thompson, Thomas R. Ioerger, Laura Simpson, Ruth Casanueva, Laura Guijarro-López, K. R. Read, Paul Graham Wyatt, Dirk Schnappinger, , Laura A. T. Cleghorn

The paper identifies and evaluates dibasic piperidines as novel cell wall inhibitors against Mycobacterium tuberculosis, showing activity across multiple media and differential sensitivity in resistant strains.

ACS Infectious Diseases · May 14, 2026Peer-reviewedBiochemistry

Design and development of lysyl tRNA synthetase inhibitors, for the treatment of tuberculosis

Susan H. Davis, Michael Mathieson, Kirsteen I. Buchanan, Alice Dawson, Alasdair Smith, Mattia Cocco, Fábio K. Tamaki, John M. Post, Beatriz Baragaña, Chimed Jansen, Michael Kiczun, Fabio Zuccotto, Gavin Wood, Paul Scullion, Peter C. Ray, , Laura A. T. Cleghorn

The paper describes the development of lysyl tRNA synthetase inhibitors for tuberculosis treatment, optimizing compounds for preclinical and potential clinical use.

Journal of Medicinal Chemistry · Aug 1, 2025Peer-reviewedMicrobiology